ESTALIS SEQUI 0.62 MG — DIN 02243529
ESTRADIOL : 0.62 MG ESTRADIOL : 4.33 MG NORETHINDRONE ACETATE : 2.7 MG · NOVARTIS PHARMACEUTICALS CANADA INC · PATCH · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ESTALIS SEQUI?
ESTALIS SEQUI 0.62 MG contains ESTRADIOL : 0.62 MG ESTRADIOL : 4.33 MG NORETHINDRONE ACETATE : 2.7 MG. It is listed in the Health Canada Drug Product Database under DIN 02243529, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Feb-2008. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ESTALIS SEQUI used for?
ESTALIS (NETA/estradiol-17ß) and ESTALIS-SEQUI (estradiol-17ß and NETA/estradiol-17ß) are indicated for the relief of menopausal and postmenopausal symptoms occurring in naturally or surgically induced estrogen deficiency states e.g. hot flushes, sleep disturbances and vulvar and vaginal atrophy. ESTALIS and ESTALIS-SEQUI are recommended for the above indication only in patients with an intact uterus since the regimen includes a progestin whose role is to prevent endometrial hyperplasia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Norethisterone And Estrogen cost around the world?
Norethisterone And Estrogen is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 4 | 5 | AUD███.██ |
| Morocco | PPV (public price) | 4 | 5 | MAD███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
15 pack listings across 13 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Norethisterone And Estrogen pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Norethisterone And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Norethisterone And Estrogen — 3 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 3 | 0 | ESTALIS SEQUI, ESTRACOMB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.62 MG |
|---|---|
| Dosage form | PATCH |
| Route | TRANSDERMAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Norethisterone And Estrogen |
|---|---|
| ATC code | G03FB05 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243529 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243529 |
| Brand name | ESTALIS SEQUI |
| Generic / active ingredient | ESTRADIOL : 0.62 MG ESTRADIOL : 4.33 MG NORETHINDRONE ACETATE : 2.7 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | G03FB05 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03FB |
| Current status | CANCELLED POST MARKET |
| Status date | 07-Feb-2008 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Applied twice weekly. Estalis: continuous combined. Estalis-Sequi: sequential (Vivelle for 14 days, then Estalis for 14 days). Use lowest effective dose for shortest period.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Estrogen-dependent neoplasia (breast/endometrial cancer); pregnancy; breast-feeding; endometrial hyperplasia; undiagnosed vaginal bleeding; porphyria; arterial/venous thromboembolic disease.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Not for cardiovascular disease prevention. Risk of endometrial cancer, gallbladder disease, and dementia (in women >65).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ESTALIS SEQUI | 4.8 MG | PATCH | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02243530 |
| ESTRACOMB | 10 MG | PATCH | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02108186 |
2 · Same class — other molecules in ATC G03FB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Norethisterone And Estrogen | ESTALIS SEQUI · ESTRACOMB | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03FA | Drospirenone And Estrogen · Ethisterone And Estrogen · Levonorgestrel And Estrogen · Medroxyprogesterone And Estrogen · Norethisterone And Estrogen · +2 more | 17 | 8 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ESTALIS SEQUI called?
The same molecule, Norethisterone And Estrogen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Primolut N | Latin | Australia, Bahrain |
| NORISTERAT | Latin | Morocco |
| AMINOR | Latin | Bahrain |
| Micro-Novum | Latin | South Africa |
| MILLIGYNON | Latin | Morocco |
| NORLUTEN | Latin | Morocco |
| PRIMOLUT-NOR | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.